Lunai Bioworks (LNAI) EBITDA Margin (2013 - 2026)

Lunai Bioworks (LNAI) recorded quarterly EBITDA Margin of 7054.05% in Q1 2026, up 97.43% quarter-over-quarter from 274996.31% in Q2 2016.

Lunai Bioworks (LNAI) EBITDA Margin (2013 - 2026) Analysis & Trends

Lunai Bioworks' EBITDA Margin history runs 3 years deep, the most recent figure standing at 7054.05% for Q1 2026.

In Q1 2026, EBITDA Margin changed N/A year-over-year to 7054.05%; the TTM figure through Mar 2026 stood at 248798.51% (changed N/A YoY), while the FY2016 annual figure was 4959.04%, changed N/A from the prior year.
EBITDA Margin was 7054.05% for Q1 2026 at Lunai Bioworks, up from 274996.31% in the prior quarter.
In the past five years, EBITDA Margin ranged from a high of 7054.05% in Q1 2026 to a low of 7054.05% in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-6.43%
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	38.10%
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Lunai Bioworks	95.85 Mn	92.70 Mn	20,942.00	-7,054.05%

Download Data